| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-94-4-482 |
| P698 | PubMed publication ID | 6782927 |
| P2093 | author name string | E C LeRoy | |
| M B Kahaleh | |||
| I Osborn | |||
| P433 | issue | 4 pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 482-484 | |
| P577 | publication date | 1981-04-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon | |
| P478 | volume | 94 |
| Q35927432 | A brief overview of the pathogenesis of scleroderma (systemic sclerosis) |
| Q33923580 | A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis |
| Q45059366 | Abnormalities in circulating von Willebrand factor and survival in pulmonary hypertension |
| Q39412123 | An investigation into the acute vascular effects of riveting. |
| Q46327770 | Anti-endothelial cell antibodies in patients with Wegener's granulomatosis and micropolyarteritis |
| Q39448876 | Antiendothelial Cell Antibodies: Useful Markers of Systemic Sclerosis |
| Q93591714 | Author's reply |
| Q37730018 | Biomarkers in systemic sclerosis |
| Q34800498 | Circulating adhesion molecules ICAM-1, E-selectin, and von Willebrand factor in Henoch-Schönlein purpura |
| Q34376033 | Circulating von Willebrand factor in inflammatory bowel disease |
| Q36824545 | Clinical aspects of systemic sclerosis (scleroderma) |
| Q68485265 | Clinical correlations of plasma angiotensin converting enzyme (ACE) activity in systemic sclerosis: a longitudinal study of plasma ACE level, endothelial injury and lung involvement |
| Q67930617 | Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus |
| Q24654517 | Dermatology |
| Q33564375 | Disseminated intravascular coagulation with renal and liver damage as the predominant manifestations of recurrent relapses in systemic juvenile rheumatoid arthritis |
| Q41101333 | Early detection and markers of sepsis |
| Q34258088 | Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome |
| Q70224799 | Elevation of von willebrand factor is independent of erythrocyte sedimentation rate and persists after glucocorticoid treatment in giant cell arteritis |
| Q73599571 | Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension |
| Q37596505 | Endothelial cells recruit macrophages and contribute to a fibrotic milieu in bleomycin lung injury |
| Q41160967 | Factor VIII related antigen in the assessment of vasculitis |
| Q69951238 | Factor VIII-von Willebrand factor in giant cell arteritis and polymyalgia rheumatica |
| Q35169066 | Fibrosis in scleroderma |
| Q61831643 | INTERMITTENT EPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROME |
| Q37351068 | IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines |
| Q70571395 | In vitro cytotoxicity of human endothelial cells in polymyalgia rheumatica and giant cell arteritis |
| Q41476445 | Increased capillary permeability in systemic sclerosis: help or hindrance? |
| Q28568900 | Injury induces increase of von Willebrand factor in rat endothelial cells |
| Q40452547 | Is Familial Mediterranean Fever a thrombotic disease or not? |
| Q71629579 | Is transdermal nicotine associated with cardiovascular risk? |
| Q68481446 | Ketanserin in the Treatment of Progressive Systemic Sclerosis |
| Q72725506 | Lowered Angiogeneic Capability of Peripheral Blood Lymphocytes in Progressive Systemic Sclerosis (Scleroderma) |
| Q38516265 | Macro- and microvascular disease in systemic sclerosis |
| Q33496078 | Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy |
| Q40697338 | Markers of disease activity in systemic sclerosis |
| Q37310583 | Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis |
| Q35169049 | Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being |
| Q33427439 | No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis |
| Q35693212 | Pathogenesis of Systemic Sclerosis |
| Q39821242 | Pathogenesis of scleroderma: the interrelationship of the immune and vascular hypotheses |
| Q35572368 | Pharmacodynamic monitoring of cyclosporin |
| Q44814935 | Physiopathologic bases of the treatment of systemic scleroderma |
| Q36890481 | Physiopathology of Raynaud phenomenon: current data |
| Q71807512 | Plasma Endothelin Correlates With Antiendothelial Antibodies in Patients With Mixed Connective Tissue Disease |
| Q68450924 | Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon |
| Q70378013 | Plasma levels of fibronectin in polymyalgia rheumatica giant cell arteritis |
| Q67595245 | Procoagulant effect of the OKT3 monoclonal antibody: involvement of tumor necrosis factor |
| Q42955705 | Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study |
| Q33693955 | Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis |
| Q41235322 | Raised concentrations of von Willebrand factor antigen in systemic sclerosis |
| Q38682561 | Raynaud's phenomenon and disease. |
| Q34560710 | Raynaud's phenomenon: epidemiology and risk factors |
| Q33631731 | Raynaud's phenomenon: its relevance to scleroderma |
| Q80792542 | Relationship between plasma cholesterol, von Willebrand factor concentrations, extent of atherosclerosis and antibody titres to heat shock proteins-60, -65 and -70 in cholesterol-fed rabbits |
| Q36283386 | Replication and phenotypic expression of control and scleroderma human fibroblasts: responses to growth factors |
| Q33579356 | Safety and efficacy of recombinant gamma interferon in the treatment of systemic sclerosis |
| Q41333515 | Scleroderma and related conditions |
| Q71761802 | Scleroderma in children |
| Q68993679 | Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy |
| Q57486499 | Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin |
| Q69880024 | Studies on endothelial cell cytotoxic activity in sera of patients with progressive systemic sclerosis, Raynaud syndrome, rheumatoid arthritis, and systemic lupus erythematosus |
| Q55447984 | Systemic Sclerosis - a Microvascular Disorder? |
| Q41984976 | Systemic sclerosis: a collagen or microvascular disease? |
| Q57244907 | The associations between plasma levels of von Willebrand factor and fibrinogen with Raynaud’s phenomenon in men and women |
| Q36824550 | The endothelium: its role in scleroderma |
| Q39595860 | The haemostatic function of the vascular endothelial cell |
| Q77296283 | Treatment with interferon gamma enhances fibrinolysis in systemic sclerosis |
| Q72925583 | Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients |
| Q37344793 | Vascular disease in scleroderma |
| Q35557424 | Vascular involvement in systemic sclerosis (scleroderma). |
| Q24796737 | Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma) |
| Q33578731 | Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis |
| Q58484365 | Von willebrand factor antigen in assessment of vasculitis in patients with connective tissue diseases |
| Q33567495 | White blood cell activation in Raynaud's phenomenon of systemic sclerosis and vibration induced white finger syndrome |
| Q33624233 | von Willebrand factor antigen compared with other factors in vasculitic syndromes |
Search more.